Trial Profile
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2022
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IMMerge
- Sponsors AbbVie
- 20 Jan 2022 Results of sub-group analysis published in the Dermatology and Therapy.
- 14 Nov 2020 This trial has been completed in Netherlands as per European Clinical Trials Database record
- 28 Jul 2020 Status changed from active, no longer recruiting to completed.